Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Total Non-current Liabilities
All obligations due after more than one year.
Aktis Oncology, Inc.NASDAQ: AKTS
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities of $42.78M in Q1 FY2026
Q1 FY2026 total non-current liabilities was $42.78M. Over 3 fiscal years it compounded at +35.6% a year.
Context
- Total non-current liabilities amounted to 7.4% of total assets at the end of Q1 FY2026.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 379.8M USD
- Year-over-year change
- -3.9%
- 3-year CAGR
- +35.6%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 379.8M | -3.9% |
| FY2024 | 2024-12-31 | 395.16M | +143.3% |
| FY2023 | 2023-12-31 | 162.42M | +6.7% |
| FY2022 | 2022-12-31 | 152.28M | — |
Total Non-current Liabilities vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 total non-current liabilities of $42.78M is the 4th highest of the 6 companies compared; the peer median is $49.19M.
- Total non-current liabilities amounts to 7.4% of total assets for AKTS, versus a peer median of 10.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $438.31M | -12.4% | +71.6% | 40.9% | |
| Mar 2026 | $100.74M | +11.9% | +16.9% | 46.2% | |
| Mar 2026 | $49.19M | -42.8% | -16.3% | 7.5% | |
| Mar 2026 | $42.78M | — | +35.6% | 7.4% | |
| Mar 2026 | $13.72M | -10.1% | -7.6% | 10.0% | |
| Sep 2026 | $10.26M | +155.6% | +296.2% | 2.0% | |
| Peer median (excluding AKTS) | $49.19M | -10.1% | +16.9% | 10.0% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.